
## Sella Provan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/211724/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumor Necrosis Factor-Î $\pm$ Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies. Hypertension, 2010, 55, 333-338.	1.3	144
2	Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in i	1.0	126
3	Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatology, The, 2022, 4, e177-e187.	2.2	122
4	Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Annals of the Rheumatic Diseases, 2011, 70, 812-817.	0.5	101
5	Carotid Plaque Characteristics and Disease Activity in Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 359-368.	1.0	89
6	Efficacy of High Intensity Exercise on Disease Activity and Cardiovascular Risk in Active Axial Spondyloarthritis: A Randomized Controlled Pilot Study. PLoS ONE, 2014, 9, e108688.	1.1	83
7	The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab. PLoS ONE, 2015, 10, e0130709.	1.1	52
8	Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2016, 43, 1622-1630.	1.0	49
9	Physical Fitness in Patients With Ankylosing Spondylitis: Comparison With Population Controls. Physical Therapy, 2012, 92, 298-309.	1.1	43
10	Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1179-1185.	0.5	38
11	Early Prediction of Increased Arterial Stiffness in Patients with Chronic Inflammation: A 15-year Followup Study of 108 Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 606-612.	1.0	37
12	NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Annals of the Rheumatic Diseases, 2010, 69, 1946-1950.	0.5	36
13	Disease Activity in Ankylosing Spondylitis and Associations to Markers of Vascular Pathology and Traditional Cardiovascular Disease Risk Factors: A Cross-sectional Study. Journal of Rheumatology, 2015, 42, 645-653.	1.0	33
14	CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up. Annals of the Rheumatic Diseases, 2015, 74, 1562-1566.	0.5	31
15	Immunogenicity and Safety of Standard and <scp>Thirdâ€Dose SARS</scp> – <scp>CoV</scp> â€2 Vaccination in Patients Receiving Immunosuppressive Therapy. Arthritis and Rheumatology, 2022, 74, 1321-1332.	2.9	31
16	Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study. Rheumatology, 2020, 59, 505-512.	0.9	29
17	Tender Joint Count and Inflammatory Activity in Patients With Established Rheumatoid Arthritis: Results From a Longitudinal Study. Arthritis Care and Research, 2020, 72, 27-35.	1.5	27
18	Evidence of reduced parasympathetic autonomic regulation in inflammatory joint disease: A meta-analyses study. Seminars in Arthritis and Rheumatism, 2018, 48, 134-140.	1.6	22

Sella Provan

#	Article	IF	CITATIONS
19	Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. RMD Open, 2018, 4, e000655.	1.8	21
20	Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naÃ⁻ve patients with spondyloarthritis. RMD Open, 2019, 5, e001079.	1.8	17
21	<scp>One‥ear</scp> Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis Care and Research, 2022, 74, 748-758.	1.5	15
22	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology, 2021, 60, 3635-3645.	0.9	14
23	Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register. Clinical and Experimental Rheumatology, 2019, 37 Suppl 116, 58-62.	0.4	10
24	How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD Open, 2020, 6, e001363.	1.8	8
25	Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors – a Nordic cohort study. Rheumatology, 2021, 60, 3656-3668.	0.9	8
26	Effects of a community-based multicomponent rehabilitation programme for patients with fibromyalgia: protocol for a randomised controlled trial. BMJ Open, 2018, 8, e021004.	0.8	8
27	Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study. Annals of the Rheumatic Diseases, 2022, 81, 398-401.	0.5	8
28	Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register. Seminars in Arthritis and Rheumatism, 2017, 46, 411-417.	1.6	7
29	The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis. Rheumatology, 2021, 60, 4121-4129.	0.9	7
30	Biomarkers of cardiovascular risk across phenotypes of osteoarthritis. BMC Rheumatology, 2019, 3, 33.	0.6	6
31	Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. RMD Open, 2020, 6, e001372.	1.8	6
32	Effectiveness of a Second Biologic After Failure of a Non–tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, 1512-1518.	1.0	5
33	Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: aÂNordic population-based cohort study. Rheumatology, 2021, 60, 140-146.	0.9	4
34	Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration. Rheumatology, 2022, 61, 4286-4296.	0.9	2
35	The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology, 2022, 61, 3647-3656.	0.9	2
36	Trajectories of change in symptom severity in patients with fibromyalgia: exploratory analyses of a randomised controlled trial. Rheumatology International, 2021, 41, 691-697.	1.5	0

#	Article	IF	CITATIONS
37	Inflammatory Joint Diseases and Risk of Cardiovascular Disease in Modern Rheumatology. Journal of Rheumatology, 2021, 48, 311-313.	1.0	0
38	Viral respiratory infections in patients treated with hydroxychloroquine. Clinical and Experimental Rheumatology, 2021, 39, 1146.	0.4	0
39	The referral of patients with fibromyalgia to a rheumatological specialist care unit. Is it necessary?. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 194.	0.4	Ο